What Influences the Growth of Canadian Biotechnology Firms?

Biotechnology ◽  
2019 ◽  
pp. 1795-1825
Author(s):  
Catherine Beaudry ◽  
Joël Levasseur

This chapter examines the influence of firm characteristics on the growth of all Canadian biotechnology firms. Data collected by Statistics Canada from four Biotechnology Uses and Development Surveys (1999, 2001, 2003 and 2005) characterise the size, origin, contracts, IP, collaboration, financing, product development stage, tax credits of Canadian biotechnology firms, while employment data from the Business Register of the organisation provides the size of firms beyond 2005. Results show the importance of collaboration for exploration (knowledge) purposes, the importance of alliances for exploitation (commercialization) purposes for firms with rapid growth. Furthermore, a good product development process that brings products through regulation towards commercialization has a positive impact on firm growth and so does R&D expenses.

Author(s):  
Catherine Beaudry ◽  
Joël Levasseur

This chapter examines the influence of firm characteristics on the growth of all Canadian biotechnology firms. Data collected by Statistics Canada from four Biotechnology Uses and Development Surveys (1999, 2001, 2003 and 2005) characterise the size, origin, contracts, IP, collaboration, financing, product development stage, tax credits of Canadian biotechnology firms, while employment data from the Business Register of the organisation provides the size of firms beyond 2005. Results show the importance of collaboration for exploration (knowledge) purposes, the importance of alliances for exploitation (commercialization) purposes for firms with rapid growth. Furthermore, a good product development process that brings products through regulation towards commercialization has a positive impact on firm growth and so does R&D expenses.


Author(s):  
Catherine Beaudry

Using the four Biotechnology Uses and Development surveys of Statistics Canada, the chapter examine the importance of collaborating with firms and public institutions at various stages of product development, from research and development to clinical trials and then on to production and commercialization. The models examine the propensity to have products at a particular stage of development using instrumental variables probit regressions. This chapter finds that while small firms do not benefit from collaborating with firms at the research and development stage, during the clinical trials and in the production phases, collaborating with firms has a strong positive effect. The factors that affect the R&D phase are R&D expenditures, an important IP strategy, revenues from contracts and to some extent contracting out some innovation activities. In later stages of the development process, the number of patents and the diversity of the biotechnology employment team play a more crucial role.


Biotechnology ◽  
2019 ◽  
pp. 1759-1794
Author(s):  
Catherine Beaudry

Using the four Biotechnology Uses and Development surveys of Statistics Canada, the chapter examine the importance of collaborating with firms and public institutions at various stages of product development, from research and development to clinical trials and then on to production and commercialization. The models examine the propensity to have products at a particular stage of development using instrumental variables probit regressions. This chapter finds that while small firms do not benefit from collaborating with firms at the research and development stage, during the clinical trials and in the production phases, collaborating with firms has a strong positive effect. The factors that affect the R&D phase are R&D expenditures, an important IP strategy, revenues from contracts and to some extent contracting out some innovation activities. In later stages of the development process, the number of patents and the diversity of the biotechnology employment team play a more crucial role.


Author(s):  
Catherine Beaudry ◽  
Joël Levasseur

This chapter aims to determine the factors, such as collaboration, research and development, intellectual property, product management and financing, that influence the survival of biotechnology firms in Canada. The research uses data from four biannual surveys on the use and development of biotechnology collected by Statistics Canada between 1999 and 2005, and follows these firms in the official business register of the organisation up to 2009, to build a Cox proportional hazard model of firm survival. The research finds that firms that collaborate for exploration purposes have better chances of survival than others. Results also suggest that a larger number of patents decreases the probability of survival. Investigation of the product development process shows that because of the vast resources necessary for clinical research, firms enter the production and commercialisation stage in a weak position, which may then result in firm exit.


Biotechnology ◽  
2019 ◽  
pp. 1498-1530
Author(s):  
Catherine Beaudry ◽  
Joël Levasseur

This chapter aims to determine the factors, such as collaboration, research and development, intellectual property, product management and financing, that influence the survival of biotechnology firms in Canada. The research uses data from four biannual surveys on the use and development of biotechnology collected by Statistics Canada between 1999 and 2005, and follows these firms in the official business register of the organisation up to 2009, to build a Cox proportional hazard model of firm survival. The research finds that firms that collaborate for exploration purposes have better chances of survival than others. Results also suggest that a larger number of patents decreases the probability of survival. Investigation of the product development process shows that because of the vast resources necessary for clinical research, firms enter the production and commercialisation stage in a weak position, which may then result in firm exit.


2011 ◽  
Vol 181-182 ◽  
pp. 25-30 ◽  
Author(s):  
Hao Hao ◽  
Bian Zhun

The pressure of financial turmoil and global competition drive domestic manufacturers to seek additional profit space besides low-cost labor and raw materials so that they could gain more competitive strength than the other companies in the world. The article maintains that in the manufacturing outsourcing environment domestic manufacturers could effectively reduce cost, shorten R&D cycle time and improve product quality in the manner of collaborative product development with outsourcing suppliers. With supply chain management and synergy theory, the article makes analysis of the definition for supplier collaboration, and then summarizes main activities of collaborative product development including specification, concept design, detail design and product design. Meanwhile, collaborative product development shall satisfy 6 key preconditions. Based on this, the article brings forwards the mechanism of collaborative product development, which is concerned with 5 phased key activities and collaborative manner from customer requirement to initial operational testing. Eventually, predict that collaborative mechanism need to be further analyzed under industry background From the beginning of the 21st century, the variation of macroscopic and microscopic environment that the global industrial field has faced was far fiercer and much more difficult to forecast than ever before. Now mass manufacture can only be accomplished by close cooperate with outsourcing partners, because of the new globalized manufacture network is becoming more and more digitized, decentralized, virtualized, intellectualized and agile. In last few decades, Chinese production has won innumerable outsourcing orders by the advantage in low cost and flexibility, which built a solid foundation of the trade surplus of China. However, in the past two years, because of the financial crisis, RMB appreciation, prices of raw material shy rocketed, and the rigorous quality and service requirement which customers always asked, the profit margin of Chinese manufacturing businesses become much smaller than ever. If these manufacturing companies keep going as before, the existing advantage they have would be soon eroded. Therefore, from ideality of supply collaborative, if these outsourcing companies can build a close relationship actively with their supplies who could significantly affect the total cost of these outsourcing companies, by using the advantages and experience these supplies have, they can design products cooperatively, save cost from the beginning, shot the development stage, and create a significant positive impact on the price and quality of the end products of these outsourcing companies


2015 ◽  
Vol 789-790 ◽  
pp. 1187-1191
Author(s):  
Olalere Folasayo Enoch ◽  
Ab. Aziz Shuaib ◽  
Abu Hassan bin Hasbullah

Successful business enterprises are to a great extent determined by strong sales and overall low operational cost; as a result, improving quality and reducing cost have been one of the important tasks for any business enterprise. These will help in achieving high quality products at reasonable price. Thus, due to the effectiveness ofSix Sigmain improving quality and reducing cost, it has become an excellent initiative that is gaining momentum in the business world. However, academics have conducted little research regarding this phenomenon, especially on it applicability in manufacturing industries. Therefore, this paper seeks the knowledge regarding howP-Diagram Model(Taguchi Method) can be applied in product development stage to achieve Design for Six Sigma (DFSS). The paper illuminates on “Process” as the basic unit for Six Sigma and how production process can be enhanced usingP-diagram. Following this understanding, the paper demonstrates how P-diagram can be applied in conceptualizing and developing product ideas that put into consideration users intent (User-centred design), reduce variations and thus, lower the risk of product failing.


Author(s):  
Bo Wang ◽  
Ping Ge

Environmental impact is becoming an important consideration in product development, such as recycling in electronics industry and air pollution in automobile industry, besides product quality and economic growth. Incorporating the environmental impact consideration into business practice as early as possible can lead to direct impact on both strategic planning in a firm and the final product, which will benefit the firm and its customers. However, many different types of business activities and levels of decision-making involved at the early stage make the simultaneous consideration of environmental impact, quality and cost hard to render. An investigation on the existing research has shown that the activity-based cost/environmental model, in a uniform representation (activity), is useful in relating business activities to the performance measures in terms of cost and environment impact resulting from these activities. In this work, the authors argue about the needs and issues on explicitly integrating quality concern into the existing activity-based cost/environmental model. The expanded model, i.e., Three-View Activity-Based Model, is intended to help construct a clear road map to represent “what is going on?” and facilitate the measure of “how well are we doing?” in a business firm with product development involved. Product quality is treated as a driver as environment and cost for the activities, which enables quantitative performance assessment of the product quality related activities. As a result of introducing the quality driver, the need to differentiate the activities directly related to product development from other activities is identified. This has led to a study on the classification of the activities and their relationship to environmental impact, product quality, and cost objectives along a product development process with life cycle considerations. The three-view activity-based model may make it possible to evaluate the effectiveness of activities against these objectives at early product development stage, and therefore, recommend changes for reshaping a firm’s strategic planning and improving current practice. Since our investigation is still at its preliminary stage, in this paper, we will present our initial results, and address research issues for the future work.


2020 ◽  
Vol 54 (s1) ◽  
pp. 15-21
Author(s):  
Vu Le ◽  
Andre Tuggles

Abstract Due to its complexity, sterilization has been perceived by some professionals who lack sterility assurance expertise as a “black box” process. Historically, medical device manufacturers have selected one of the available industrial sterilization options: dry heat, moist heat, gamma, or ethylene oxide (EO). The preselection of a sterilization modality (method) typically is made without understanding its impact based on qualified sterilization processes for existing products, capability, or resources required for the specific processes. Early engagement with sterilization subject matter experts (SMEs) can redirect the decision to preselect a legacy modality and help foster innovation and operational agility. Recent focus on supply chain flexibility and sustainability by the medical device industry has been affected by concerns surrounding cobalt-60 shortages and EO emissions. These factors drive the need for early involvement with sterility assurance SMEs in the product development process and the exploration of multiple sterilization modalities. This article highlights the importance of exploring multiple sterilization modalities during the product development stage to support sustainable business continuity plans.


Sign in / Sign up

Export Citation Format

Share Document